Clinical trial
Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to…
NCT00245245 · Octagen Corporation, Industry · Completed
Key facts
| NCT number | NCT00245245 |
|---|---|
| Title | Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII |
| Official title | An Open-Label Study of the Hemostatic Activity, Pharmacokinetics and Safety of OBI-1 (B-Domain Deleted Recombinant Porcine FVIII), When Administered by Intravenous Injection, to Control Non-Life and Non-Limb Threatening Bleeding Episodes in Congenital Hemophilia A Patients With an Inhibitor to Human… |
| Lead sponsor | Octagen Corporation, Industry |
| Collaborators | Biomeasure Inc, Ipsen Group Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hemophilia A |
| Intervention type | Drug |
| Interventions | recombinant porcine coagulation factor VIII (OBI-1) |
| Enrollment | 12 |
| Start date | May 1, 2005 |
| Completion | Jun 1, 2007 |
| First posted | Oct 27, 2005 |
| Last update posted | Oct 4, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: